FDA clears CSL’s swelling disease drug; Regeneron loses 23andMe auction

The agency cleared CSL’s hereditary angioedema drug days after “resource constraints” delayed a rival medicine. Elsewhere, Intellia revealed new data and Lilly beefed up an online service offering access to Zepbound. 

Jun 17, 2025 - 16:20
 0
FDA clears CSL’s swelling disease drug; Regeneron loses 23andMe auction

The agency cleared CSL’s hereditary angioedema drug days after “resource constraints” delayed a rival medicine. Elsewhere, Intellia revealed new data and Lilly beefed up an online service offering access to Zepbound.